Finerenone in the management of Diabetic Kidney Disease: A consensus statement by the Association of British Clinical Diabetologists and UK Kidney Association

This consensus statement by the Association of British Clinical Diabetologists and UK Kidney Association provides context and recommendations regarding the use Finerenone in the management of Diabetic Kidney Disease.

Discipline

Diabetes Endocrinology
Resource taxonomy
Position Paper
Clinical taxonomy
Chronic kidney disease Type 2 diabetes mellitus
Listing status
Current

ABCD Corporate Pharma Sponsors

Gold

  • AstraZeneca UK
  • Boehringer Ingelheim and Lilly Alliance
  • Eli Lilly and Company

Silver

  • A Menarini Farmaceutica Internazionale SRL
  • Sanofi

ABCD Corporate Pump & Device Sponsors

Gold

  • Abbott
  • Dexcom
  • Ypsomed Ltd

Silver

  • A. Menarini Diagnostics
  • Advanced Therapeutics (UK) Ltd
  • Air Liquide Healthcare Ltd
  • Insulet International
  • Medtronic Limited

Bronze

  • Roche Diabetes Care

Contact

Address for correspondence: 
ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602
Email: info@abcd.care

Follow Us

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd